Fibrinolytic function and coronary risk

被引：29

作者：

Juhan-Vague I. ^{[1
]}

Morange P. ^{[1
]}

Alessi M.C. ^{[1
]}

机构：

[1] Laboratoire d'Hématologie, CHU Timone

来源：

Current Cardiology Reports | 1999年 / 1卷 / 2期

关键词：

Arterioscler Thromb Vasc Biol; Human Adipose Tissue; Plasminogen Activator Inhibitor Type; Activator Mass Concentration; Endogenous Fibrinolysis;

D O I：

10.1007/s11886-999-0069-x

中图分类号：

学科分类号：

摘要：

Plasminogen activation potential in the blood is controlled by an equilibrium between plasminogen activators, mainly tissue-type plasminogen activator (t-PA), and inhibitors, mainly plasminogen activator inhibitor (PAI)-1. In cardiovascular practice, imbalance of this fibrinolytic potential is encountered primarily in the insulin-resistance syndrome. This syndrome leads to increased plasma PAI-1 and t-PA antigen levels (reflecting inactive t-PA/PAI-1 complexes) with a consequent decrease in fibrinolytic activity. Increased plasma PAI-1 and t-PA antigen both are predictive of myocardial infarction. The prognostic value of PAI-1 disappears after adjustments for insulin resistance markers, whereas the prognostic value of t-PA antigen disappears after simultaneous adjustments for insulin resistance and inflammation markers, suggesting an additive role of inflammation in inducing plasma fibrinolytic markers. Recently the production of PAI-1 by adipose tissue, in particular by tissue from the omentum, has been shown. PAI-1 produced in this way could be an important contributor to the elevated plasma PAI-1 levels observed in insulin-resistant patients. These results support the notion that PAI-1 may be a link between obesity, insulin resistance, and cardiovascular disease. Genetic control of PAI-1 expression has also been shown, involving a - 675 4G/5G polymorphism, the 4G/4G genotype being associated with higher plasma PAI-1 levels; its proper influence on the development of myocardial infarction is still debated. Copyright © 1999 by Current Science Inc.

引用

页码：119 / 124

页数：5

共 70 条

[1]

Collen D., Lijnen H.R., Basic and clinical aspects of fibrinolysis and thrombolysis, Blood, 78, pp. 3114-3124, (1991)

[2]

Reilly C.F., Fujita T., Hutzelmann J.E., Et al., Plasminogen activator inhibitor 1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism, Circulation, 84, pp. 287-292, (1991)

[3]

Erickson L.A., Fici G.J., Lund J.E., Et al., Development of venous occlusions in mice transgenic for the PAI-1 gene, Nature, 346, pp. 74-76, (1990)

[4]

Carmeliet P., Bouche A., De Clercq C., Et al., Biological effects of disruption of the tissue-type plasminogen activator, urokinase type plasminogen activator and plasminogen activator inhibitor-1 genes in mice, Ann NY Acad Sci, 748, pp. 367-382, (1995)

[5]

Farrehi P.M., Ozaki C.K., Carmeliet P., Et al., Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice, Circulation, 97, pp. 1002-1008, (1998)

[6]

Stefansson S., Lawrence D.A., The serpin PAI-1 inhibits cell migration by blocking integrin avb3 binding to vitronectin, Nature, 323, pp. 441-443, (1996)

[7]

Deng G., Curriden S.A., Wang S., Et al., Is plasminogen activator inhibitor 1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?, J Cell Biol, 134, pp. 1563-1571, (1996)

[8]

Chandler W.L., Alessi M.C., Aillaud M.F., Et al., Clearance of t-PA and t-PA/PAI-1 complex: Relationship to elevated t-PA antigen in patients with high PAI-1 activity levels, Circulation, 96, pp. 761-768, (1997)

[9]

Juhan-Vague I., Alessi M.C., Fibrinolysis and risk of coronary artery disease, Fibrinolysis, 10, pp. 127-136, (1996)

[10]

Scarabin P.Y., Aillaud M.F., Amouyel P., Et al., Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction, Thromb Haemost, 80, pp. 749-756, (1998)

← 1 2 3 4 5 6 7 →